Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 211Recurrence 27Neoplasms, Plasma Cell 15Neoplasms 13Immunoglobulin Light-chain Amyloidosis 13Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Smoldering Multiple Myeloma 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Hematologic Neoplasms 4Plasmacytoma 3Paraproteinemias 3Myelodysplastic Syndromes 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Amyloidosis 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Plasmablastic Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Disease 2Corneal Diseases 2Blood Protein Disorders 2

Interventions

Cytarabine 14fludarabine 13venetoclax 11Imatinib Mesylate 9Cyclophosphamide 8Azacitidine 8fludarabine phosphate 7Busulfan 7Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6thymoglobulin 4ponatinib 4nilotinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4asciminib 3aldesleukin 3Melphalan 3Interleukin-2 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Decitabine 3Antilymphocyte Serum 3zosuquidar trihydrochloride 2gilteritinib 2enasidenib 2blinatumomab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia, Myeloid × daratumumab × Clear all
NCT04714372 2024-10-24

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
9 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡